SCHEMBL3868598

SCHEMBL3868598

N#Cc1ccccc1CSc1nc2ccccc2c(=O)n1CC1CCC(C(N)=O)(C(=O)OCCc2ccccc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ HTT P42858 2/20 0.44
▸ ATM Q13315 1/20 0.44
▸ NPSR1 Q6W5P4 3/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KMT2A Q03164 1/20 0.42
▸ PLA2G1B P04054 1/20 0.42
▸ ATG4B Q9Y4P1 1/20 0.42
▸ CA12 O43570 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA9 Q16790 3/20 0.40
▸ CA1 P00915 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HIF1A Q16665 2/20 0.40
▸ CNR2 P34972 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867745 0.84 CA2 (0.52) ALDH1A1HTTNPSR1TDP1L3MBTL1
SCHEMBL3868593 0.78 TNKS (0.56) ALDH1A1HTTATMTDP1KMT2A
SCHEMBL6520222 0.67 KMT2A (0.49) ALDH1A1TDP1KMT2ALMNATNKS
SCHEMBL2354757 0.66 KMT2A (0.58) ALDH1A1HTTATMNPSR1TDP1
SCHEMBL7693183 0.65 KCNH2 (0.45) ALDH1A1TDP1L3MBTL1CYP3A4CYP1A2
SCHEMBL12024152 0.64 HTT (0.58) ALDH1A1HTTATMNPSR1TDP1
SCHEMBL2357637 0.64 CYP3A4 (0.61) ALDH1A1HTTATMNPSR1TDP1
SCHEMBL24533635 0.61 CYP3A4 (0.60) ALDH1A1HTTATMNPSR1TDP1
SCHEMBL3867743 0.60 KMT2A (0.59) ALDH1A1HTTNPSR1TDP1L3MBTL1
SCHEMBL24533634 0.60 TSHR (0.81) ALDH1A1HTTNPSR1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065703-A1 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM THERAPEUTICS LLC 2011-03-17 — — US claimed
EP-2073799-A2 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM Discovery, Inc. (US) 2009-07-01 — — EP claimed
WO-2008112715-A2 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM DISCOVERY INC. (US) 2008-09-18 — — WO claimed
US-8586619-B2 Agents of calcium ion channel modulators VM THERAPEUTICS LLC (US) 2013-11-19 — — US disclosed
US-20110065703-A1 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM THERAPEUTICS LLC 2011-03-17 — — US disclosed
EP-2073799-A2 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM Discovery, Inc. (US) 2009-07-01 — — EP disclosed
WO-2008112715-A2 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS VM DISCOVERY INC. (US) 2008-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065703-A1 NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS CACNA1G, CACNA1C, CACNA1B ALDH1A1 4124/4885HTT 886/4885ATM 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback